Abstract
Introduction
In 2006 the United Nations recognised diabetes as a global epidemic, the first non-infectious disease to be acknowledged as posing a worldwide health threat (1) . The estimated global prevalence for adults aged 20-70 in 2015 was 415 million and this is expected to rise to 642 million by 2040 (2) . Type 2 diabetes (T2DM) is responsible for approximately 90% of the diagnosed cases although a significant number of people with T2DM, approximately 1 in 2 (46%), remain undiagnosed (3). It is more common in deprived communities (75% of adults with T2DM live in low or middle income countries) and 5 million people die from diabetes-related illness each year (3). In the UK it's estimated to account for 10% of total NHS spend, largely due to the long-term complications caused by diabetes. Good glycaemic control reduces the risk of complications (4, 5, 6) , particularly microvascular ones such as kidney disease and visual loss.
A healthy lifestyle is the cornerstone of T2DM management. Diet and exercise modifications are usually followed by or combined with pharmacological therapy. Metformin is the initial treatment of choice (7, 8) in the majority of indivduals with T2DM. If the combination of metformin and healthy lifestyle fails to control glycaemia, additional glucose lowering medication is added.
Traditionally the next step was a sulphonylurea due to its efficacy, low cost acquisition and availability. However as a result of glucose-lowering studies such as ACCORD (9) and ADVANCE (10) , current guidelines (7, 8) recognise that treatment should be tailored to the individual. The result of this is that many different therapeutic options can and should be considered as possible 2 nd line treatments. These include thiazolidinediones (7, 8) , glucagon-like peptide-1 receptor agonists (GLP-1 RA) (8) , sodium-glucose cotransporter 2 (SGLT2) inhibitors (7), DPP-4 inhibitors (7, 8) and insulin (8) . Failure to achieve adequate control at this point would typically lead to triple therapy using combinations of the above medications.
T2DM occurs as a consequence of insulin resistance, and inadequate insulin secretion. Under normal circumstances nutrients in the small intestine and raised blood glucose levels lead to the release of incretin peptides, Glucagon-like peptide-1 (GLP-1) and Gastrointestinal peptide (GIP) into the circulation. These peptides cause a glucose-dependent release of insulin by activating Gprotein coupled receptors on the surface of pancreatic β cells whilst GLP-1 also reduces hepatic glucose production by inhibiting glucagon secretion from islet α cells. The incretin peptides have a short plasma half life (1-2 minutes) as they undergo rapid enzymatic degradation by DPP-4. T2DM is associated with a significant reduction in GLP-1 production and intravenous infusion of GLP-1 restores normoglycaemia (11) ; hence elevation of endogenous GLP-1 levels by inhibiting it's destruction was seen as a therapeutic target. Inhibition of DPP-4 using oral DPP-4 inhibitors, leads to an increased concentration of endogenous GLP-1 and GIP resulting in significant improvements in glycaemic control, and appears to have a greater efficacy in Asians than Caucasians (12) . In addition, since insulin release induced by DPP-4 inhibitors is glucose-dependent, it is associated with significantly fewer episodes of hypoglycaemia than traditional therapy with sulphonylureas.
Eleven DPP-4 inhibitors have now been approved for use in man. There are seven once daily DPP-4 inhibitors: alopgliptin, evogliptin, gemigliptin, linagliptin, saxagliptin, sitagliptin, and teneligliptin; two twice daily anagliptin and vildagliptin; and two once weekly trelagliptin and omarigliptin (13) .
Whilst these have different characteristics based on their unique chemical structures, clinical trials have failed to demonstrate a significant difference in efficacy. HbA1c reductions of 0.6-0.8% are typically recorded compared to placebo at the end of 12-24 week trials. Generally they are well tolerated, with low rates of hypoglycaemia unless added to insulin or insulin secretagogues (such as sulphonylureas), and are weight neutral, unlike sulphonylureas, insulin and thiazolidinediones which lead to weight gain.
Body of Review

Overview of the market
Type 2 diabetes is a chronic, lifelong condition which exposes sufferers to an increased risk of vascular complications. The complications can be divided broadly into macrovascular (cerebrovascular, cardiovascular and peripheral vascular disease) and microvascular (retinopathy, nephropathy and neuropathy). In addition to not smoking, key elements of management include control of blood pressure, lipids and glucose levels. As a result individuals with type 2 diabetes are often required to take multiple drug therapies in an attempt to control these risk factors but compliance has been shown to be poor (14) . The development of once weekly products may simplify complex daily regimens and aid compliance.
Until March 2015 the only DPP-4 inhibitors available on the market were once or twice daily products. Since then two new once weekly gliptins have been approved in Japan (13), trelagliptin (March 2015) and omarigliptin (September 2015). Whether once weekly gliptin preparations will improve compliance and as a consequence glycaemic control remains to be seen but they are a welcome addition to the market.
Introduction to the compound
Omarigliptin is a once weekly dipetidyl peptidase-4 (DPP-4) inhibitor. Produced by Merck & Co.
Inc., it received regulatory authority in Japan in September 2015 for monotherapy, or dual and triple therapy with other oral hypoglycaemics (15). It is generally prescribed at a dose of 25mg once weekly. There is no required dose reduction in mild or moderate renal impairment, but it needs to be reduced to 12.5mg once weekly in severe renal impairment (eGFR <30mls/minute/1.73m
2 ).
There are no dose restrictions with any degree of hepatic impairment (16).
Chemistry
The molecular formula of omarigliptin (MK-1032) is C 17 H 20 F 2 N 4 O 3 S, (Box 1), with a molecular weight of 394.4 g/mol.
Omarigliptin is created by a reductive amination of tetrahydropyranone with methylsulfonylpyrrolopyrazole in the presence of triacetoxyborohydride in dimethylacetal. The intermediates produced by this are then subject to deprotection and neutralisation with ammonium hydroxide, and crystallisation from ethyl acetate to form omarigliptin (17).
Pharmacodynamics
Omarigliptin inhibitors it is well tolerated, weight neutral and has a low incidence of symptomatic hypoglycaemia (19).
Pharmacokinetics and metabolism
Omarigliptin is a reversible competitive inhibitor of DPP-4, which is more potent than sitagliptin the current market leader (IC 50 omarigliptin 1.6nM, sitagliptin 18nM) (17). The pharmacokinetic profile of omarigliptin is biphasic with a long terminal half-life of >100 hours which allows for a once weekly dosing regimen. It is rapidly absorbed, the AUC and Cmax of omarigliptin is proportional to the dose used, reaching a steady state within 2-3 weeks. (17, 18). There is minimal accumulation after multiple dosing, which suggests that omarigliptin reaches therapeutic levels with the first dose (18).
The pharmacokinetic profile of omarigliptin has been shown to be the same in obese individuals with and without T2DM (18 
Phase II
In a 12 week phase II, double-blind, randomised, dose ranging study assessing the effect of omarigliptin 0.25mg, 1mg, 3mg, 10mg or 25mg once weekly against placebo in individuals with T2DM the greatest improvement in glycaemic control was seen with the 25mg dose of omarigliptin (19) . There was a significant (p<0.001) improvement in HbA1c -0.72% (-0.93, -0.5), 2 hour post meal glucose -2.5 mmol/L (-3.3, -1.7), and fasting plasma glucose -1.3 mmol/L at 12 weeks.
Similarly a greater proportion of individuals on omarigliptin 25mg once weekly achieved the HbA1c target <7.0% (33.6% v 21.8%), or <6.5% (13.6% v 4.5%) compared with placebo.
Subjects completing the baseline study (18) were eligible to join a 66 week extension study (Table   1 ). All individuals in the omarigliptin arm, including those initially on 25mg, were given omarigliptin 25mg once weekly whilst the placebo arm were initially treated with blinded In a 24 week, phase III, head to head study in subjects with T2DM (Table 1) inadequately controlled on metformin, omarigliptin 25mg once weekly achieved its primary endpoint and was non-inferior to sitagliptin 100mg once daily at reducing HbA1C levels from baseline (omarigliptin -0.47%; sitagliptin -0.43% (difference -0.03% [95% CI -0.15 to 0.08])). In addition, a similar number of patients achieved an HbA1C <6.5% (omarigliptin 27%; sitagliptin 23% (p=0.212)) (23).
A 54 week, head-to-head, phase III trial in people with T2DM (Table 1) In a recently completed phase III, multicenter, randomized, double-blind, placebo-controlled trial (Table 1 ) the addition of omarigliptin 25mg once weekly to individuals with T2DM inadequately controlled on a combination of metfomin and glimepiride (triple therapy) significantly reduced HbA1c by -0.67% (-0.84 to -0.50) compared with placebo -0.06% (-0.23 to 0.12) (p<0.001) (25) .
The omarigliptin arm also achieved its secondary endpoint targets of a significant reduction in fasting plasma glucose compared to placebo (-1.1 v -0.2 mmol/L (p<0.001)) and a significantly higher percentage attained HbA1c target of <7.0% (23.8% v 4.4% (p<0.001)) and <6.5% (10.1% v 2.1% (p<0.01)).
Ongoing trials of interest:
Phase III trials designed to assess the safety and efficacy of omarigliptin in young adults (26) , and those with increasingly severe renal impairment including established haemodialysis (27) have recently completed and results are awaited.
Safety and Tolerability
The adverse events in phase I and II studies have tended to be mild and transient. The most frequently reported adverse events attributed to omarigliptin were headaches, dizziness, and nausea (17, 28). There have been no consistent abnormalities in the history, physical examination, laboratory safety tests (lipids (TC, HDL, LDL & Tg), liver function, creatinine kinase, creatinine and eGFR) or ECG studies, including a detailed QTc study (29) .
Omarigliptin is largely renally excreted. Phase I studies have identified the need to reduce the dose from 25mg to 12.5mg once weekly in presence of severe renal impairment (eGFR <30mls/minute/1.73m 2 ) or end stage renal disease but no adjustment is required with hepatic impairment (16) .
Adverse event data in Phase III trials appears to be consistent with safety data from Phase I and II trials. In a recent phase III study comparing omarigliptin 25mg once weekly against sitagliptin 100mg OD a similar number experienced serious (omarigliptin 11 (3.4%) verses sitagliptin 9 (2.8%)) or drug related (omarigliptin 123 (3.7%) verses sitagliptin 12 (3.8%)) adverse events, and there was no significant difference in the number who discontinued (omarigliptin 3 (0.9%) verses sitagliptin 7 (2.2%) 95% CI -3.6 to 0.8) in both study arms. Symptomatic and asymptomatic hypoglycaemia was recorded in 3.7% of the omarigliptin group (one severe) compared with 4.7% of the sitagliptin group, whilst the commonest recorded adverse events were diarrhoea, influenza, urinary tract infection, lipase increase and back pain ( Table 2) .
A randomized, double-blind, placebo-controlled study assessing cardiovascular outcomes following treatment with omarigliptin in 4000 subjects with T2DM has recently been terminated by Merck as it no longer plans to submit a marketing application in the United States or Europe (30) . There were no additional efficacy or safety concerns reported during this study.
Interactions:
Omarigliptin does not inhibit cytochrome p450s (CYPIA2, 2B6, 2C8, 2C9, 2C19, 2D6, 3A4), phase 2 enzymes (UGTIA1, SULTIE1) or key drug transporters (human P-gp, BCRP, OATPIB1, OATPIB3, hOAT1, hOAT3, hOCT1, hOCT2) nor does it induce CYP1A2, CYP2B6 or CYP3A4. It therefore has low risk of drug-drug interactions.
Post-marketing surveillance
Omarigliptin was launched in Japan during the last quarter of 2015. To date post marketing surveillance studies have not been published.
In summary the incidence of hypoglycaemia is low and comparable to placebo. There are currently no significant concerns identified to suggest that omariglitpin has a different safety profile to daily dosed DPP-4 inhibitors.
Regulatory affairs
Omarigliptin received regulatory authority in Japan in September 2015 for monotherapy, or dual and triple therapy with other oral hypoglycaemics (15). Currently there are no plans to submit additional marketing applications.
Conclusion
Omarigliptin is a once weekly DPP-4 inhibitor with equivalent efficacy to once daily preparations.
The therapeutic effect of DPP-4 inhibitors relates to their effectiveness in inhibiting DPP-4 enzyme rather than a direct end-organ effect. Since the DPP-4 inhibitors generally have a similar effect on the enzyme they have equivalent efficacy.
The incidence of hypoglycaemia is low and comparable to placebo but in keeping with all DPP-4 inhibitors will be increased when combined with sulphonylureas or insulin. To date, no significant concerns have been identified to suggest that omarigliptin has a different safety profile to daily dosed DPP-4 inhibitors. It appears to have a low risk of drug-drug interactions.
Omarigliptin has a licence for mono, dual or triple therapy and is prescribed at a dose of 25mg once weekly. There is no required dose reduction in mild or moderate renal impairment, but it needs to be reduced to 12.5mg once weekly in severe renal impairment (eGFR <30mls/minute/1.73m 2 ).
Expert opinion
Whilst diet and lifestyle remain the cornerstone of T2DM management there is a need to develop safe, efficacious treatments which improve compliance. Omarigliptin is the second once weekly DPP-4 inhibitor to be licenced. It results in a significant improvement in glycaemia with an effective once weekly pharmacokinetic profile. It has equivalent efficacy to existing once daily DPP-4 inhibitors, and shares a similar side effect profile. Omarigliptin is weight neutral with a significantly lower risk of hypoglycaemia than sulphonylureas. Deterioration in glycaemic control was seen at the end of an 18 month extension study, as seen with other glucose lowering treatments which do not appear to impact on the progressive nature of hyperglycaemia in T2DM.
The they are all currently injectable agents and so many patients will prefer less frequent administration.
In addition, there is emerging evidence that long-acting GLP1-RA therapy may have cardiovascular advantages over shorter acting agents.
In Japan, metformin has never achieved the primacy over other anti-diabetes therapies seen in the West. Sulphonylureas have headed traditional guidelines and here the DPP-4 inhibitors have made major in-roads into the diabetes therapies marketplace. This is due to their advantages of low hypoglycaemia and weight neutrality over the sulphonylureas. So, for many clinicians, DPP-4s are the first line therapy for T2DM and the option of once weekly omarigliptin versus daily therapies is more obvious. It may also represent a more 'gradual' introduction of treatment which may be attractive for patients. Whether once weekly omarigliptin will improve compliance and, thereby, produce better levels of glycaemic control in real-world conditions remains to be seen. respectively) not only showed non-inferiority but were also found to be superior with respect to their CV endpoint. If these results are confirmed as class effects, generalisable to T2DM patients at lower levels of CV risk than those included in the current trials, then it is likely that DPP-4 inhibitors will move down the treatment algorithms. This will especially be the case if the on-going development of an oral GLP-1RA (semaglutide) is successful. In this scenario, further development of the largely off-patent DPP-4 class may be limited. 
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